Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders.

Schizophrenia bulletin - 7 Sept 2023

Li Xiaoyan, Shen Aotian, Zhao Yiran, Xia Junfeng

Abstract excerpt

BACKGROUND AND HYPOTHESIS: Psychiatric disorders impose a huge health and economic burden on modern society. However, there is currently no proven completely effective treatment available, partly owing to the inefficiency of drug target identification and validation. We aim to identify therapeutic targets relevant to psychiatric disorders by conducting Mendelian randomization (MR) analysis. STUDY DESIGN: We...

Topics

Join the communities discussing this publication.

Attention Deficit Disorder with Hyperactivity
Autism Spectrum Disorder
Bipolar Disorder
Genome-Wide Association Study
Mendelian Randomization Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 37418754
DOI: 10.1093/schbul/sbad100
PMCID: PMC10483453

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders.PMID 37418754Read ↗

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders.Semantic proximity Read ↗

Identifying drug targets for neurological and psychiatric disease via genetics and the brain transcriptome.Semantic proximity Read ↗

Dissecting the shared genetic landscape of anxiety, depression, and schizophrenia.Semantic proximity Read ↗

Genetically informed drug target prioritisation and repurposing for major depressive disorderSemantic proximity Read ↗

Linking GWAS to pharmacological treatments for psychiatric disordersSemantic proximity Read ↗

Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds.Semantic proximity Read ↗

Mendelian randomization analysis of the brain, cerebrospinal fluid, and plasma proteome identifies potential drug targets for attention deficit hyperactivity disorder.Semantic proximity Read ↗

Prioritization of novel druggable targets for epilepsy via Mendelian randomization and colocalization.Semantic proximity Read ↗

Leveraging the Genetics of Psychiatric Disorders to Prioritize Potential Drug Targets and CompoundsSemantic proximity Read ↗

Psychiatric genome-wide association study enrichment shows promise for future psychopharmaceutical discoveriesSemantic proximity Read ↗

Causal effects of lipid-lowering drug targets on psychiatric disorders: A drug-target Mendelian randomization study.Semantic proximity Read ↗

Advancing the use of genome-wide association studies for drug repurposing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.